Literature DB >> 19520863

Differential effect of membrane cholesterol removal on mu- and delta-opioid receptors: a parallel comparison of acute and chronic signaling to adenylyl cyclase.

Erica S Levitt1, Mary J Clark, Paul M Jenkins, Jeffrey R Martens, John R Traynor.   

Abstract

According to the lipid raft theory, the plasma membrane contains small domains enriched in cholesterol and sphingolipid, which may serve as platforms to organize membrane proteins. Using methyl-beta-cyclodextrin (MbetaCD) to deplete membrane cholesterol, many G protein-coupled receptors have been shown to depend on putative lipid rafts for proper signaling. Here we examine the hypothesis that treatment of HEK293 cells stably expressing FLAG-tagged mu-opioid receptors (HEK FLAG-mu) or delta-opioid receptors (HEK FLAG-delta) with MbetaCD will reduce opioid receptor signaling to adenylyl cyclase. The ability of the mu-opioid agonist [D-Ala2,N-Me-Phe4,Gly5-ol]enkephalin to acutely inhibit adenylyl cyclase or to cause sensitization of adenylyl cyclase following chronic treatment was attenuated with MbetaCD. These effects were due to removal of cholesterol, because replenishment of cholesterol restored [D-Ala2,N-Me-Phe4,Gly5-ol]enkephalin responses back to control values, and were confirmed in SH-SY5Y cells endogenously expressing mu-opioid receptors. The effects of MbetaCD may be due to uncoupling of the mu receptor from G proteins but were not because of decreases in receptor number and were not mimicked by cytoskeleton disruption. In contrast to the results in HEK FLAG-mu cells, MbetaCD treatment of HEK FLAG-delta cells had no effect on acute inhibition or sensitization of adenylyl cyclase by delta-opioid agonists. The differential responses of mu- and delta-opioid agonists to cholesterol depletion suggest that mu-opioid receptors are more dependent on cholesterol for efficient signaling than delta receptors and can be partly explained by localization of mu- but not delta-opioid receptors in cholesterol- and caveolin-enriched membrane domains.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19520863      PMCID: PMC2755935          DOI: 10.1074/jbc.M109.030411

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  62 in total

1.  Residence of adenylyl cyclase type 8 in caveolae is necessary but not sufficient for regulation by capacitative Ca(2+) entry.

Authors:  Karen E Smith; Chen Gu; Kent A Fagan; Biao Hu; Dermot M F Cooper
Journal:  J Biol Chem       Date:  2001-12-13       Impact factor: 5.157

2.  Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells.

Authors:  M Encinas; M Iglesias; Y Liu; H Wang; A Muhaisen; V Ceña; C Gallego; J X Comella
Journal:  J Neurochem       Date:  2000-09       Impact factor: 5.372

Review 3.  Use of detergents to study membrane rafts: the good, the bad, and the ugly.

Authors:  Hidehiko Shogomori; Deborah A Brown
Journal:  Biol Chem       Date:  2003-09       Impact factor: 3.915

Review 4.  Molecular mechanisms for heterologous sensitization of adenylate cyclase.

Authors:  Val J Watts
Journal:  J Pharmacol Exp Ther       Date:  2002-07       Impact factor: 4.030

5.  Agonist-, antagonist-, and inverse agonist-regulated trafficking of the delta-opioid receptor correlates with, but does not require, G protein activation.

Authors:  P A Zaki; D E Keith; J B Thomas; F I Carroll; C J Evans
Journal:  J Pharmacol Exp Ther       Date:  2001-09       Impact factor: 4.030

6.  Regulation of the Ca2+-inhibitable adenylyl cyclase type VI by capacitative Ca2+ entry requires localization in cholesterol-rich domains.

Authors:  K A Fagan; K E Smith; D M Cooper
Journal:  J Biol Chem       Date:  2000-08-25       Impact factor: 5.157

7.  Differential targeting of beta -adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae. A mechanism to functionally regulate the cAMP signaling pathway.

Authors:  V O Rybin; X Xu; M P Lisanti; S F Steinberg
Journal:  J Biol Chem       Date:  2000-12-29       Impact factor: 5.157

8.  Unbiased quantitative proteomics of lipid rafts reveals high specificity for signaling factors.

Authors:  Leonard J Foster; Carmen L De Hoog; Matthias Mann
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-30       Impact factor: 11.205

9.  Localization of adenylyl cyclase isoforms and G protein-coupled receptors in vascular smooth muscle cells: expression in caveolin-rich and noncaveolin domains.

Authors:  Rennolds S Ostrom; Xiaoqiu Liu; Brian P Head; Caroline Gregorian; Tammy M Seasholtz; Paul A Insel
Journal:  Mol Pharmacol       Date:  2002-11       Impact factor: 4.436

10.  Endogenous RGS protein action modulates mu-opioid signaling through Galphao. Effects on adenylyl cyclase, extracellular signal-regulated kinases, and intracellular calcium pathways.

Authors:  Mary J Clark; Charlotte Harrison; Huailing Zhong; Richard R Neubig; John R Traynor
Journal:  J Biol Chem       Date:  2003-01-10       Impact factor: 5.157

View more
  26 in total

1.  Cholesterol regulates micro-opioid receptor-induced beta-arrestin 2 translocation to membrane lipid rafts.

Authors:  Yu Qiu; Yan Wang; Ping-Yee Law; Hong-Zhuan Chen; Horace H Loh
Journal:  Mol Pharmacol       Date:  2011-04-25       Impact factor: 4.436

2.  Differential sensitivity of types 1 and 2 cholecystokinin receptors to membrane cholesterol.

Authors:  Ross M Potter; Kaleeckal G Harikumar; S Vincent Wu; Laurence J Miller
Journal:  J Lipid Res       Date:  2011-10-21       Impact factor: 5.922

Review 3.  Sarcolemmal dependence of cardiac protection and stress-resistance: roles in aged or diseased hearts.

Authors:  Louise E See Hoe; Lauren T May; John P Headrick; Jason N Peart
Journal:  Br J Pharmacol       Date:  2016-09-09       Impact factor: 8.739

4.  Sarcolemmal cholesterol and caveolin-3 dependence of cardiac function, ischemic tolerance, and opioidergic cardioprotection.

Authors:  Louise E See Hoe; Jan M Schilling; Emiri Tarbit; Can J Kiessling; Anna R Busija; Ingrid R Niesman; Eugene Du Toit; Kevin J Ashton; David M Roth; John P Headrick; Hemal H Patel; Jason N Peart
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-07-25       Impact factor: 4.733

Review 5.  Allostery at opioid receptors: modulation with small molecule ligands.

Authors:  Kathryn E Livingston; John R Traynor
Journal:  Br J Pharmacol       Date:  2017-06-07       Impact factor: 8.739

Review 6.  Molecular Pharmacology of δ-Opioid Receptors.

Authors:  Louis Gendron; Catherine M Cahill; Mark von Zastrow; Peter W Schiller; Graciela Pineyro
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

7.  Biased μ-opioid receptor agonists diversely regulate lateral mobility and functional coupling of the receptor to its cognate G proteins.

Authors:  Barbora Melkes; Lucie Hejnova; Jiri Novotny
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-09-06       Impact factor: 3.000

8.  Desensitization and trafficking of μ-opioid receptors in locus ceruleus neurons: modulation by kinases.

Authors:  Seksiri Arttamangkul; Elaine K Lau; Hsin-Wei Lu; John T Williams
Journal:  Mol Pharmacol       Date:  2011-11-23       Impact factor: 4.436

9.  Heterodimerization with the prostacyclin receptor triggers thromboxane receptor relocation to lipid rafts.

Authors:  Salam Ibrahim; Ann McCartney; Nune Markosyan; Emer M Smyth
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-11-15       Impact factor: 8.311

Review 10.  Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.

Authors:  John T Williams; Susan L Ingram; Graeme Henderson; Charles Chavkin; Mark von Zastrow; Stefan Schulz; Thomas Koch; Christopher J Evans; Macdonald J Christie
Journal:  Pharmacol Rev       Date:  2013-01-15       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.